정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 933 | Enrolling by invitation | Ozone Plasma on Lung Function and Inflammatory Parameters in Pulmonary Sequelae Associated With Coronavirus 19 Infection | COVID-19 | Drug: Ozone plasma | Phase 2 | Centro Universitario de Ciencias de la Salud, Mexico | OTHER | 35 | All | 25 Years ~ 80 Years | Fernando Grover Paez, Guadalajara, Jalisco, Mexico Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara, Guadalajara, Jalisco, Mexico |
| 932 | Recruiting | P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 | COVID19 | Drug: P2Et (Caesalpinia spinosa extract) Other: Placebo |
Phase 3 | Hospital Universitario San Ignacio, Pontificia Universidad Javeriana | OTHER | 100 | All | 18 Years | Hospital Universitario San Ignacio, Bogota, Colombia |
| 931 | Recruiting | Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19 | COVID-19 | Biological: SARS-CoV-2 Specific T Cells | Phase 2 | KK Women's and Children's Hospital, Duke-NUS Graduate Medical School, National University Hospital, Singapore, Singapore General Hospital, Sengkang General Hospital, Changi General Hospital | OTHER_GOV | 18 | All | 1 Year ~ 90 Years | Changi General Hospital, Singapore, Singapore KK Women's and Children's Hospital, Singapore, Singapore National University Hospital, Singapore, Singapore Sengkang General Hospital, Singapore, Singapore Singapore General Hospital, Singapore, Singapore |
| 930 | Completed | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | SARS-CoV-2 | Biological: pathogen reduced SARS-CoV-2 convalescent plasma Biological: Placebo |
Phase 3 | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | OTHER | 974 | All | 18 Years | University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States Scripps Health, La Jolla, California, United States University of Colorado Denver, Aurora, Colorado, United States MedStar Health Research Institute/MedStar Washington Hospital Center, Washington, District of Columbia, United States Cleveland Clinic Florida, Weston, Florida, United States University of Chicago, Chicago, Illinois, United States Loyola University Medical Center, Maywood, Illinois, United States The University of Kansas Medical Center, Kansas City, Kansas, United States Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States University of Maryland, Baltimore (University of Maryland Medical Center), Baltimore, Maryland, United States Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States Newton-Wellelsey Hospital, Newton, Massachusetts, United States University of Minnesota, Minneapolis, Minnesota, United States University of Mississippi Medical Center, Jackson, Mississippi, United States University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States University at Buffalo/Buffalo General Medical Center, Buffalo, New York, United States Rochester General Hospital, Rochester, New York, United States Cleveland Clinic Ohio, Cleveland, Ohio, United States The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, Ohio, United States Vanderbilt University Medical Center, Nashville, Tennessee, United States Meharry Medical College, Nashville, Tennessee, United States Utah Valley Hospital, Provo, Utah, United States University of Utah Health, Salt Lake City, Utah, United States Sentara Norfolk General Hospital, Norfolk, Virginia, United States Virginia Commonwealth University, Richmond, Virginia, United States University of Washington, Seattle, Washington, United States |
| 929 | Terminated | PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine | Corona Virus Infection | Drug: Group 1 HCQ Drug: Group 2 Placebo |
Phase 2 | UnitedHealth Group, ProHealth Care Associates, University of Pennsylvania Perelman School of Medicine | INDUSTRY | 39 | All | 18 Years ~ 75 Years | ProHealth New York, New York, New York, United States |
| 928 | Terminated | Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection | Sars-CoV2 | Drug: Peginterferon lambda alfa-1a subcutaneous injection Other: Saline |
Phase 2 | Johns Hopkins University, Eiger BioPharmaceuticals | OTHER | 6 | All | 18 Years ~ 80 Years | Johns Hopkins Hospital, Baltimore, Maryland, United States |
| 927 | Active, not recruiting | Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19) | Covid19 | Drug: Pegylated Interferon-α2b Other: Standard of Care |
Phase 2 | Cadila Healthcare Limited | INDUSTRY | 40 | All | 18 Years | Avant Sante site 2, Zapopan, Jalisco, Mexico Avant Sante Site 1, Monterrey, Mexico |